Positive Signs for Lecanemab's Full Approval in FDA Briefing Documents

(MedPage Today) -- Lecanemab (Leqembi) showed clinical benefit in early Alzheimer's disease and its risks do not appear to preclude traditional approval, FDA reviewers said in a briefing document ahead of an advisory committee meeting.
The document...